Sandor Schoichet

Outlining the most important sustainability-related hurdles facing leading biopharma companies today—and current efforts underway to meet new expectations in advancing this strategic mandate.

Meaningful biopharma sustainability metrics are a crucial challenge.

Biopharma sustainability resolutions for a better 2021.

Why major companies are stepping up environmental commitments.

SynBio opens new environmental sustainability possibilities for pharma.

Biopharma must find sustainable models for public policy engagement.

ESG objectives are integral to long-term biopharma strategy.

The need for clear transparency around use of real-world data, AI.